INCY
Price
$126.75
Change
-$1.25 (-0.98%)
Updated
Sep 4 closing price
Capitalization
25.95B
60 days until earnings call
Intraday BUY SELL Signals
RIGL
Price
$48.67
Change
+$0.17 (+0.35%)
Updated
Sep 4 closing price
Capitalization
904.67M
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INCY vs RIGL

INCY vs RIGL Comparison Chart in %
View a ticker or compare two or three
VS
INCY vs. RIGL commentary
Sep 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and RIGL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2026
Stock price -- (INCY: $128.00 vs. RIGL: $48.50)
Brand notoriety: INCY: Notable vs. RIGL: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 54% vs. RIGL: 65%
Market capitalization -- INCY: $25.95B vs. RIGL: $904.67M
INCY [@Biotechnology] is valued at $25.95B. RIGL’s [@Biotechnology] market capitalization is $904.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $141.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 3 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 3 green, 2 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both INCY and RIGL are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 3 TA indicator(s) are bullish while RIGL’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 3 bullish, 5 bearish.
  • RIGL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а +0.20% price change this week, while RIGL (@Biotechnology) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.43%. For the same industry, the average monthly price growth was +6.98%, and the average quarterly price growth was +2391.73%.

Reported Earning Dates

INCY is expected to report earnings on Nov 03, 2026.

RIGL is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (+1.43% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($25.9B) has a higher market cap than RIGL($905M). INCY has higher P/E ratio than RIGL: INCY (16.31) vs RIGL (2.87). INCY YTD gains are higher at: 29.594 vs. RIGL (13.238). INCY has higher annual earnings (EBITDA): 2.07B vs. RIGL (131M). INCY has more cash in the bank: 4.54B vs. RIGL (147M). INCY has less debt than RIGL: INCY (38.3M) vs RIGL (45.7M). INCY has higher revenues than RIGL: INCY (5.82B) vs RIGL (300M).
INCYRIGLINCY / RIGL
Capitalization25.9B905M2,862%
EBITDA2.07B131M1,579%
Gain YTD29.59413.238224%
P/E Ratio16.312.87569%
Revenue5.82B300M1,940%
Total Cash4.54B147M3,086%
Total Debt38.3M45.7M84%
FUNDAMENTALS RATINGS
INCY vs RIGL: Fundamental Ratings
INCY
RIGL
OUTLOOK RATING
1..100
7281
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
3380
SMR RATING
1..100
339
PRICE GROWTH RATING
1..100
1036
P/E GROWTH RATING
1..100
7297
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RIGL's Valuation (44) in the Biotechnology industry is somewhat better than the same rating for INCY (87). This means that RIGL’s stock grew somewhat faster than INCY’s over the last 12 months.

INCY's Profit vs Risk Rating (33) in the Biotechnology industry is somewhat better than the same rating for RIGL (80). This means that INCY’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's SMR Rating (9) in the Biotechnology industry is in the same range as INCY (33). This means that RIGL’s stock grew similarly to INCY’s over the last 12 months.

INCY's Price Growth Rating (10) in the Biotechnology industry is in the same range as RIGL (36). This means that INCY’s stock grew similarly to RIGL’s over the last 12 months.

INCY's P/E Growth Rating (72) in the Biotechnology industry is in the same range as RIGL (97). This means that INCY’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYRIGL
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
56%
Bearish Trend 23 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signal:
Gain/Loss:
RIGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFIAX16.260.08
+0.49%
Columbia Flexible Capital Income A
RYMPX280.36N/A
N/A
Rydex Precious Metals H
ASPCX27.74N/A
N/A
Alger Spectra C
WPVLX30.90N/A
N/A
Weitz Multi Cap Equity-Investor Cl
FBCHX300.98N/A
N/A
Fidelity Advisor Blue Chip Growth C